Noelia Casares

List of Publications by Year in Descending Order

62 papers	7,460 citations	29 h-index	70 g-index
70 ext. papers	8,392 ext. citations	8.3 avg, IF	4.68 L-index

#	Paper	IF	Citations
62	Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy.. *OncoImmunology*, **2022**, 11, 2070337	7.2	1
61	Impact of tumor microenvironment on adoptive T cell transfer activity. *International Review of Cell and Molecular Biology*, **2022**,	6	0
60	Olfactory Characterization and Training in Older Adults: Protocol Study. *Frontiers in Aging Neuroscience*, **2021**, 13, 757081	5.3	
59	TCR-induced FOXP3 expression by CD8 T cells impairs their anti-tumor activity.. *Cancer Letters*, **2021**, 528, 45-45	9.9	1
58	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. *Journal of Nanobiotechnology*, **2021**, 19, 102	9.4	15
57	Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma. *BioMed Research International*, **2021**, 2021, 8852233	3	1
56	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. *Emerging Microbes and Infections*, **2021**, 10, 1931-1946	18.9	6
55	Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens **2020**, 8,		2
54	Cellular cytotoxicity is a form of immunogenic cell death **2020**, 8,		23
53	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-*Journal of Immunology*, **2019**, 203, 696-704	5.3	4
52	Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma. *Journal of Vascular and Interventional Radiology*, **2019**, 30, 1098-1105	2.4	7
51	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. *Blood*, **2019**, 133, 2401-2412	2.2	29
50	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. *Nature Medicine*, **2019**, 25, 1073-1081	50.5	71
49	FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells. *Anticancer Research*, **2019**, 39, 5369-5374	2.3	2
48	Genetic Modification of CD8 T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. *Frontiers in Immunology*, **2019**, 10, 2990	8.4	9
47	A new immune-nanoplatform for promoting adaptive antitumor immune response. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2019**, 17, 13-25	6	9
46	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. *Frontiers in Immunology*, **2018**, 9, 68	8.4	11

45	The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. *OncoImmunology*, **2018**, 7, e1409321	7.2	8
44	Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. *Haematologica*, **2018**, 103, 1065-1072	6.6	6
43	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming. *Cancer Research*, **2018**, 78, 6643-6654	10.1	40
42	Expansion of Tumor-Infiltrating CD8 T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. *Cancer Research*, **2017**, 77, 3672-3684	10.1	62
41	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. *Nature Communications*, **2017**, 8, 15424	17.4	74
40	Therapeutic blockade of Foxp3 in experimental breast cancer models. *Breast Cancer Research and Treatment*, **2017**, 166, 393-405	4.4	11
39	Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10-Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. *Diabetes*, **2017**, 66, 448-459	0.9	46
38	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. *Frontiers in Immunology*, **2017**, 8, 594	8.4	8
37	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. *Oncotarget*, **2017**, 8, 71709-71724	3.3	16
36	Targeting inhibition of Foxp3 by a CD28 2'Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. *Biomaterials*, **2016**, 91, 73-80	15.6	37
35	MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells. *Oncotarget*, **2016**, 7, 23182-96	3.3	48
34	Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine. *PLoS ONE*, **2016**, 11, e0161216	3.7	8
33	Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. *Journal of Immunology*, **2015**, 195, 3180-9	5.3	34
32	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. *Oncotarget*, **2015**, 6, 27160-75	5.3	39
31	Searching for the Achilles Heel of FOXP3. *Frontiers in Oncology*, **2013**, 3, 294	5.3	18
30	A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo. *BioMed Research International*, **2013**, 2013, 864720	3	14
29	Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. *Vaccine*, **2012**, 30, 2848-58	4.1	17
28	Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. *International Journal of Cancer*, **2012**, 131, 641-51	7.5	28

27	Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. *Journal of Experimental Medicine*, **2011**, 208, 491-503	16.6	261
26	Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. *Journal of Hepatology*, **2011**, 54, 422-31	13.4	58
25	A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. *Journal of Immunology*, **2010**, 185, 5150-9	5.3	79
24	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. *Cell Cycle*, **2010**, 9, 2902-2907	4.7	5
23	Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis. *Vaccine*, **2010**, 28, 7146-54	4.1	8
22	Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. *International Journal of Cancer*, **2009**, 125, 2614-23	7.5	51
21	Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes. *Scandinavian Journal of Immunology*, **2009**, 69, 80-9	3.4	7
20	Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. *Journal of Hepatology*, **2009**, 51, 520-7	13.4	19
19	In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. *Journal of Immunology*, **2008**, 181, 126-35	5.3	56
18	Calreticulin exposure dictates the immunogenicity of cancer cell death. *Nature Medicine*, **2007**, 13, 54-61	50.5	2026
17	The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. *Journal of Immunology*, **2007**, 178, 748-56	5.3	82
16	Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. *Journal of Virology*, **2007**, 81, 3662-6	6.6	99
15	A novel dendritic cell subset involved in tumor immunosurveillance. *Nature Medicine*, **2006**, 12, 214-9	50.5	340
14	Apoptosis regulation in tetraploid cancer cells. *EMBO Journal*, **2006**, 25, 2584-95	13	153
13	Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. *Journal of Experimental Medicine*, **2005**, 202, 1691-701	16.6	934
12	Inhibition of macroautophagy triggers apoptosis. *Molecular and Cellular Biology*, **2005**, 25, 1025-40	4.8	1411
11	Increased immunogenicity of colon cancer cells by selective depletion of cytochrome C. *Cancer Research*, **2004**, 64, 2705-11	10.1	17
10	AIF deficiency compromises oxidative phosphorylation. *EMBO Journal*, **2004**, 23, 4679-89	13	522

9	Immune response against dying tumor cells. *Advances in Immunology*, **2004**, 84, 131-79	5.6	94
8	Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses. *International Immunology*, **2003**, 15, 691-9	4.9	1
7	A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. *Hepatology*, **2003**, 37, 461-70	11.2	21
6	CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. *Journal of Immunology*, **2003**, 171, 5931-9	5.3	169
5	Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. *Journal of Virology*, **2002**, 76, 5062-70	6.6	131
4	Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. *Vaccine*, **2002**, 21, 202-10	4.1	47
3	Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. *European Journal of Immunology*, **2001**, 31, 1780-9	6.1	73
2	T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. *International Immunology*, **1999**, 11, 2025-34	4.9	19
1	Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. *Hepatology*, **1998**, 28, 815-22	11.2	71